Tyme Investor Relations Material

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) for patients with a broad range of cancers. The company is developing THOR, a synthetic retinoid prodrug designed to be an orally active anticancer agent in the treatment of cancers. It offers Thymidylate synthase (TYMS) inhibitors and other chemicals used in research. The company has clinical stage product candidates under clinical development and preclinical stage programs under nonclinical development.